Novo Nordisk A/ S Stock: FDA Approval for Awiqli Bolsters Diabetes Portfolio Amid 2026 Market Recovery

Novo Nordisk A/S (ISIN: DK0062498333) secures FDA approval for once-weekly basal insulin Awiqli, targeting type 2 diabetes patients ahead of its 2026 US rollout. This development reinforces the company's leadership in diabetes care for North American investors seeking stable growth in pharmaceuticals.

Novo Nordisk A/S, a global leader in diabetes and obesity treatments, continues to shape the pharmaceutical landscape with recent FDA approval for its innovative once-weekly basal insulin, Awiqli. This milestone, announced on March 27, 2026, positions the drug for a US launch in 2026, enhancing the company's competitive edge in the basal insulin market.

As of: 28.03.2026

By Elena Vargas, Senior Financial Editor at NorthStar Market Insights: Novo Nordisk A/S drives innovation in diabetes management, offering North American investors exposure to high-demand therapies in a consolidating sector.

Recent FDA Approval Strengthens Product Pipeline

The US Food and Drug Administration approved Awiqli, Novo Nordisk's once-weekly basal insulin for adults with type 2 diabetes, on March 27, 2026. This insulin icodec injection offers a convenient dosing schedule compared to daily options, potentially improving patient adherence.

Approval came after positive clinical trial data demonstrating effective blood sugar control. Novo Nordisk plans a US rollout in 2026, expanding its diabetes franchise that includes blockbuster drugs like Ozempic and Wegovy.

This addition diversifies Novo Nordisk's portfolio beyond GLP-1 agonists, addressing a key segment in diabetes care. For investors, it signals sustained innovation amid growing global demand for diabetes treatments.

Stock Performance and Valuation Metrics

Shares of Novo Nordisk A/S (NOVO B, ISIN: DK0062498333) trade on Nasdaq Copenhagen in Danish kroner (DKK). As of market close on March 27, 2026, the stock reflected recent pressures, with a reported 5-day decline amid broader European market jitters.

Valuation metrics highlight attractiveness: forward P/E ratio for 2026 at 10.9x and 10.8x for 2027, with expected dividend yields of 4.69% in 2026 rising to 4.92% in 2027. Enterprise value to sales multiples stand at 3.94x for 2026 and 3.72x for 2027, suggesting reasonable pricing relative to growth prospects.

The company maintains a free-float of 70.25%, supporting liquidity. North American investors access the stock via ADRs (NVO) on the NYSE, providing familiar trading in USD.

Recent institutional activity includes Romano Brothers and Company increasing its stake by 704% in Q4 2025, holding 34,236 shares valued at approximately $1.742 million. Such moves indicate confidence from US-based funds.

Core Business Model in Diabetes and Obesity

Novo Nordisk focuses primarily on diabetes care, which accounts for the bulk of its revenue, alongside growing obesity treatments. The company's portfolio features GLP-1 receptor agonists like semaglutide, marketed as Ozempic for diabetes and Wegovy for weight management.

Diabetes remains a global epidemic, with rising prevalence driving demand. Novo Nordisk's strategy emphasizes innovation in delivery systems, such as oral formulations, where Wegovy prescriptions reached strong levels early in its market entry.

Obesity treatments represent a high-growth area, with Novo Nordisk leading alongside competitors. The firm's R&D pipeline targets next-generation therapies, bolstering long-term revenue potential.

Geographically, North America is a key market, contributing significantly to sales through established reimbursement channels and high diabetes incidence rates.

Competitive Landscape and Sector Drivers

In the GLP-1 space, Novo Nordisk faces rivalry from Eli Lilly, particularly with Mounjaro and Zepbound. Despite 2025 challenges, including a reported 40% stock drop, Novo has rebounded 22% in 2026, reflecting resilience.

Sector drivers include aging populations, lifestyle diseases, and expanding indications for weight-loss drugs, such as cardiovascular benefits. Regulatory approvals, like Awiqli, help maintain market share.

Novo Nordisk's scale— with market capitalization around 1,014 billion DKK—provides resources for R&D and manufacturing. Its free-float ensures broad investor participation.

Broader pharmaceutical trends favor companies with strong patent cliffs navigation and pipeline depth, areas where Novo excels.

Relevance for North American Investors

For US and Canadian investors, Novo Nordisk offers exposure to Europe's top pharma stock via NYSE-listed ADRs. The ADR structure simplifies trading, dividend receipts, and corporate action participation.

Dividend policy remains shareholder-friendly, with approval of final 2025 dividend payable in March 2026 at DKK 11.70 total, as noted in recent AGM discussions. Yields above 4% appeal to income-focused portfolios.

Tax treaties between Denmark and North America mitigate withholding taxes on dividends. Currency exposure to DKK adds diversification, though hedged products exist.

Growth in US diabetes prevalence—over 38 million cases—aligns with Novo's strengths. Awiqli's approval directly enhances US revenue potential.

Risks and Key Factors to Watch

Competition intensifies in GLP-1 and insulin markets, with patent expirations looming medium-term. Profitability pressures appeared in 2025, with EPS declines noted, though demand remains robust.

Regulatory hurdles, pricing pressures from US payers, and supply chain issues for high-demand drugs pose challenges. Geopolitical tensions have contributed to recent European stock volatility.

Analyst views mixed: Barclays neutral, Goldman Sachs neutral with adjusted targets, Zacks upgrading to hold. Investors should monitor Q1 2026 earnings for pipeline progress.

What to watch: Awiqli US launch execution, Wegovy prescription trends, competitor trial results, and macro factors like interest rates affecting valuations. Regulatory updates on expanded indications will be pivotal.

Supply constraints for obesity drugs persist, but Novo Nordisk's manufacturing investments aim to address them. Dividend sustainability ties to cash flow from core franchises.

Broader risks include healthcare policy shifts in the US, such as drug pricing reforms, impacting margins. Currency fluctuations between DKK and USD affect ADR performance.

North American investors should track FDA decisions, sales data from IQVIA, and peer comparisons quarterly. Long-term, demographic trends favor diabetes leaders like Novo.

Overall, Novo Nordisk A/S balances innovation with proven execution, making it a watchlist staple for diversified pharma exposure.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.